Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Advanced Drainage Systems (NYSE:WMS) from Neutral to ...

Fintel reports that on January 8, 2025, UBS downgraded their outlook for JELD-WEN Holding (NYSE:JELD) from Buy to Neutral.

UBS analysts upgrade Bank of America (BAC) to Buy from Neutral and lift their price target to $53 from $43. The analysts ...

The Swiss bank expects the city’s benchmark index to rise above 20,000 by year-end, implying a gain of 3.7 per cent from ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Investing.com -- Nvidia (NASDAQ: NVDA ), Microsoft (NASDAQ: MSFT ), and OpenAI are the key AI beneficiaries, UBS analysts said, citing results of its latest enterprise AI survey. The survey, which ...

Mark Sullivan manages $800 million in client assets and is joining Procyon, while St. Petersburg, Fla.-based advisor Mary ...

Shares in Computershare lowered in early trading on the ASX after UBS downgraded its rating on the share registry firm.

Tesla Inc. could collect more than €1 billion ($1 billion) in compensation from rival automakers that need help meeting ...

周三，UBS分析师Jo Walton将诺和诺德公司股票评级从卖出上调至买入，但目标价从此前的750.00丹麦克朗下调至750.00丹麦克朗。这一立场的改变是基于对GLP-1药物市场需求积极转变的预期，而诺和诺德公司正是专门生产这类药物的。

AI stocks and the "Magnificent Seven" were clear winners in 2024. But after a solid year of growth and high valuations, will that momentum continue in 2025? Perhaps, says UBS. In a note, UBS head of U ...